Merck doubles down on Galapagos discovery deal

Merck is doubling down on its research collaboration with Galapagos. Building on a deal struck at the beginning of the year, Merck has boosted its commitment on milestones for new atherosclerosis therapies to more than €400 million. In the pact, Galapagos will be responsible for the discovery and pre-clinical development of new small molecule candidate drugs based on novel Galapagos targets. "Merck's extended collaboration with Galapagos underscores our ongoing commitment to identifying novel therapeutic targets for fighting cardiovascular and metabolic diseases," said Merck's Catherine Strader. Galapagos release